| Margins | Investing in energy efficiency; 3.8 Cr capital investment for efficiency. |
|---|---|
| Management confidence | High regarding sustainability goals and decarbonization journey. |
Growth
Achieved 73% reduction in carbon emissions vs FY21 base. Renewable energy share in total mix reached 63% in FY25.
Outlook
Targets carbon neutral operations by 2030 and 100% renewable power by 2030. Planned ESG risk screening for critical suppliers by FY2027.
Risks
Identified climate-related risks and water stress; 20% of freshwater requirement is sourced from water-stressed regions.
Last quarter's promises, checked
Delivered
- Guided R&D 2.5-3% of sales → delivered 2.8% (= BEAT)
- Guided EBITDA margin 25-26% → delivered 25.4% (= BEAT)
- Guided capex ~5% of revenue → delivered 5.2% (= BEAT)
Partly delivered
- Guided double-digit OTC growth → delivered 9% for FY26 (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,474.90
- Market cap
- ₹1,02,225 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.0×Sector 50.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Investor Presentation: Key Takeaways
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma Q1 FY27 Results: Net Profit ₹574.1 Cr, Up 29.1% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,031 Cr (+12.9% YoY) and net profit of ₹574.1 Cr (+29.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹574.1 Cr · +29.1% YoY
Mankind Pharma Earnings Call: Key Takeaways
Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.